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Abstract
Background—Colorectal cancers (CRCs) with the CpG island methylator phenotype (CIMP) often
associate with epigenetic silencing of hMLH1 and an activating mutation in the BRAF gene. However,
the current CIMP criteria are ambiguous, and often result in an underestimation of CIMP frequencies
in CRCs. Since BRAF and KRAS belong to same signaling pathway, we hypothesized that not only
mutations in BRAF, but mutant KRAS, may also associate with CIMP in CRC.
Methods—We determined the methylation status of a panel of 14 markers (7 canonical CIMP-
related loci, and 7 new loci), MSI status, and BRAF/KRAS mutations in a cohort of 487 colorectal
tissues that included both sporadic and Lynch syndrome patients.
Results—Methylation analysis of seven CIMP-related markers revealed that the mean number of
methylated loci was highest in BRAF mutated CRCs [3.6], versus KRAS-mutated [1.2; P<0.0001] or
BRAF/KRAS wild-type tumors [0.7; P<0.0001]. However, analyses with seven additional markers
showed that the mean number of methylated loci in BRAF mutant tumors [4.4] was the same as in
KRAS mutant CRCs [4.3; P=0.8610]. Although sporadic MSI-H tumors had the most average number
of methylated markers [8.4], surprisingly Lynch syndrome CRCs also demonstrated frequent
methylation [5.1].
Conclusions—CIMP in CRC may result from activating mutations in either BRAF or KRAS, and
the inclusion of additional methylation markers that correlate with mutant KRAS may help clarify
CIMP in future studies. Additionally, aberrant DNA methylation is a common event not only in
sporadic CRC, but also in Lynch syndrome CRCs.
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Introduction
Aberrant promoter hypermethylation associated with transcriptional silencing of multiple
tumor suppressor genes has been proposed as a mechanistic component in the evolution of
several human cancers 1. Tumors with a critical degree of aberrant methylation have the CpG
Island Methylator Phenotype (CIMP), which was initially described in the colorectal cancer
(CRC) 2. CIMP, microsatellite instability (MSI) and chromosomal instability constitute the
three major mechanisms of genomic or epigenetic instability in CRC 3,4. Since the initial
description of CIMP, its role in carcinogenesis has been controversial 3,5–7. Experimental
evidence has consistently supported the presence of CIMP in a subset of CRCs 3,4,8,9, and it
has been found that CIMP significantly correlates with a V600E mutation in the BRAF gene
10,11. However, some degree of promoter methylation can be found in normal tissues and
virtually all CRCs, so some have argued that CIMP does not constitute a unique pathogenetic
pathway 7.
Due to the controversy surrounding CIMP, many laboratories have focused on making a case
that CIMP constitutes a discrete group of CRCs through the identification of an optimized
panel of CIMP-specific markers 11–13. Two panels of CIMP-specific markers have been
proposed, including those identified by the originators of the concept12,13, and a second panel
recently reported after an extensive evaluation of a very large group of candidate markers 11.
Both panels are highly specific for the identification of CIMP CRCs with BRAF V600E
mutations 11. However, there is a lack of consensus on the frequency of CIMP in CRC, because
of multiple definitions of CIMP (CIMP+ and CIMP−, CIMP-high and low, etc.), the use of
different sets of methylation markers, and differences in diagnostic methodologies. However,
the greatest challenge has been to use consistent criteria for CIMP analyses to categorize a
cancer positive or negative for this phenotype, and finding a consensus for the definition of
CIMP 8,9,14,15.
Nearly all of the approximately 15% of sporadic MSI CRCs come from a CIMP background,
caused by the epigenetic silencing of hMLH1; however, additional CRCs that are microsatellite
stable (MSS) may also be labeled as CIMP depending upon the diagnostic criteria used 4,8,
9. It has been proposed that CIN and CIMP represent two major mechanisms of genomic (or
epigenetic) instability in CRC, and that perhaps upto 50% of CRCs might be characterized as
having CIMP 4. Thus, it is important to have a more complete understanding of CIMP, and to
reach a consensus on whether this constitutes a unique and unified group of tumors that may
evolve through a common pathway.
CIMP determinations using CIMP-related markers have consistently identified clusters of
CRCs with MSI and V600E BRAF mutations, but rarely KRAS mutations 8,9,14,16. However,
when additional methylation loci have been investigated, additional subsets of CRCs have been
identified with extensive methylation; these tumors are MSS, and are associated with mutations
in the KRAS gene 4,17,18. Although these tumors should be considered CIMP-positive, they
have been typically categorized as non-CIMP, because, by definition, analyses using the
canonical CIMP criteria considered only those methylation events strictly associated with
mutant BRAF. Defining the markers in this fashion raises a possible problem of circular
reasoning.
BRAF and KRAS gene products function in the same serial signaling pathway, and activating
mutations in these genes are usually mutually exclusively 10,19. Interestingly, prior to the more
recent discovery of V600E BRAF mutations, KRAS mutations were proposed as the possible
cause of aberrant methylation. It has been shown that fibroblasts transformed by fos or ras
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experience upregulation of DNA methyltransferase (DNMT) expression and consequent global
hypermethylation 20.
In light of these considerations, we hypothesized that CIMP in CRC may not be exclusively
the result of mutations in BRAF, but might be a more general consequence of the upregulation
of the RAS-RAF pathway. In the present study, we investigated the relationship between the
activating mutations of the BRAF/KRAS genes and global hypermethylation using a broad panel
of methylation markers that included both the canonical CIMP-related markers, and additional
methylation-related loci. We included in our investigation a group of Lynch syndrome-related
CRCs, in which there is MSI, but no mutations in BRAF. We found that methylation of this
broad panel of methylation markers segregates not just with BRAF, but also with KRAS
mutations. Our data provide novel evidence for a potential role of KRAS mutations in the
evolution of aberrant methylation, and propose a broader panel of methylation markers that
may improve our current understanding for the molecular basis of CIMP.
Materials and Methods
Colorectal tissue specimens
We obtained a cohort of 487 colorectal tissues, including 243 cancers, 208 corresponding
normal colonic mucosal specimens from patients with CRC (C-N), and 36 normal epithelial
tissues from patients without any evidence of neoplasia at colonoscopy (N-N) from Okayama
University Hospital, Okayama, Japan and Heidelberg University, Heidelberg, Germany. Of
the 243 CRCs, 21 cancers were from Lynch syndrome patients, and had documented germline
mutations and associated loss of protein expression of the MMR genes: hMSH2, hMLH1,
hPMS2, and hMSH6; the remaining 222 were sporadic CRCs, in which patients did not have
any family history of CRC, and had no evidence for polyposis or IBD. Among 222 sporadic
CRCs, 184 cases have been previously analyzed for CIMP 17. Normal mucosal tissues were
sampled from distant surgical margins of the CRC resections. All patients provided written
informed consent, and the studies were approved by Institutional Review Boards of all
institutions involved.
Sodium bisulfite modification and Combined Bisulfite Restriction Assays (COBRA)
Genomic DNA obtained from colorectal tissues was bisulfite modified to convert all
unmethylated cytosine residues to uracils. Bisulfite PCR reactions were carried out and
restriction endonuclease digestion was performed on PCR products for methylation analyses
of 14 markers (Table 1) 21. Seven methylation markers were canonical CIMP-related loci,
including the hMLH1-5’ region, hMLH1-3’ region, p16INK4a, p14ARF, MINT1, MINT2, and
MINT31 4,5,16. We then analyzed methylation frequencies at promoter regions of seven
additional tumor suppressor genes that have been reported to be frequently methylated in a
cancer-specific manner in CRC (SFRP2, RASSF2A, MGMT, Reprimo, 3OST2, HPP1, and
APC) 22–29.
The digested DNA was separated on 3% agarose gels and stained with ethidium bromide. The
quantitative methylation levels (ratios of methylated to unmethylated DNA) were determined
from the relative intensities of cleaved and non-cleaved PCR products. A marker was
considered methylation positive if it showed ≥5% methylation density, and methylation
negative if it had <5%, in accordance with canonical CIMP criteria 12.
Microsatellite Analysis
Microsatellite analysis of each tumor tissue was determined using the NCI-workshop panel of
recommended markers 30. Tumors showing a shift in at least one mononucleotide marker and
one other marker were classified as MSI-H, and were referred to as MSI cancers throughout
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the text. We then analyzed all non-MSI tumors with five additional dinucleotide repeat
sequences (D5S107, D8S87, D17S261, D18S35, and D18S58) and one tetranucleotide repeat
marker (MYCL1). MSI-Low (MSI-L) was defined as a shift in any of the dinucleotide and/or
tetranucleotide markers; tumors which showed no allelic shifts were classified as microsatellite
stable (MSS) 31. We grouped 55 MSI-L and 152 MSS together as non-MSI cancers in this
study for comparative purposes because both have similar clinicopathologic, and mutational
features.
BRAF and KRAS mutation analysis
Direct sequencing was performed to identify BRAF V600E mutation and KRAS codon 12/13
mutations. Primer sequences for BRAF and KRAS were: BRAF-F (5′-
TGCTTGCTCTGATAGGAAAATGA-3′), BRAF-R (5′-
TGGATCCAGACAACTGTTCAAA-3′), KRAS-F (5′-GCCTGCTGAAAATGACTGAA-3′)
and KRAS-R (5′-AGAATGGTCCTGCACCAGTAA-3′) that generated fragment lengths of
165 and 167 bp, respectively. PCR products were purified using a QIAquick PCR purification
kit (Qiagen) and directly sequenced on an ABI 3100-Avant DNA sequencer.
Statistical analyses
The methylation status of 14 epigenetic markers was analyzed as a categorical variable
(methylated: methylation level ≥5%, unmethylated: methylation level <5%). CRCs were
divided into subgroups according to MSI/LS or BRAF/KRAS mutation status, and the
relationship of each epigenetic marker with various clinico-pathological parameters was
evaluated using the X2 test. We used Kruskal-Wallis one way analysis of variance on rank sums
to compare overall differences in the average number of methylated loci among subgroups
classified by MSI status (sporadic MSI or Lynch syndrome) or BRAF/KRAS mutation status.
Whenever the Kruskal-Wallis test indicated differences among these subgroups, further pair-
wise comparisons for each of the subgroups divided by MSI/Lynch Syndrome or BRAF/
KRAS mutation status was performed using a non-parametric multiple comparison method
using Steel-Dwass test. In order to ascertain the relative risks for methylation, we calculated
the odds ratio (OR) of each CRC subgroup according to methylation at each epigenetic marker.
A 95% confidence interval (CI) was calculated for each OR. All reported P values are 2-sided
and a P<0.05 was considered statistically significant.
Results
V600E BRAF mutations are frequently present in sporadic MSI CRCs, while KRAS mutations
are exclusively observed in Lynch syndrome and non-MSI CRCs
A total of 487 colorectal tissues, including 243 CRCs, 208 C-Ns, and 36 N-Ns were
investigated. All tumors were categorized into subgroups depending upon their MSI status
(sporadic or Lynch syndrome), and BRAF/KRAS mutations. We found that 36/243 (15%) CRCs
were MSI and 207/243 (85%) were non-MSI. Among the 36 MSI tumors, 15 (42%) were
sporadic MSI CRCs, while 21 (58%) were from Lynch syndrome patients (which had been
oversampled for this analysis). To highlight the differences between Lynch syndrome and
sporadic MSI tumors, we categorized all CRCs into three subsets based upon BRAF/KRAS
mutation status as sporadic MSI, Lynch syndrome and non-MSI cancers. We observed that 8%
(20/243) of the CRCs harbored V600E BRAF mutations (“BRAF mutant”), 33% (80/243) had
KRAS codon 12 or 13 mutations (“KRAS mutant”), and 59% (143/243) CRCs lacked mutations
in both BRAF and KRAS genes (“wild type”).
Table 2 illustrates detailed associations between the CRC groups based upon MSI status
(sporadic MSI and Lynch syndrome), and mutation spectrum (BRAF/KRAS). We observed that
a significant proportion of sporadic MSI CRCs occurred in patients ≥65 years of age (80%),
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which was similar to the frequency in non-MSI patients (51%), but as anticipated, the age was
significantly lower in Lynch syndrome CRCs (5%, Lynch syndrome vs. sporadic MSI or non-
MSI; P<0.0001). Sporadic MSI tumors were more frequent in females than males (sporadic
MSI, 60%; Lynch syndrome, 19%; Non-MSI, 35%). Also, 92% of sporadic MSI and 69% of
Lynch syndrome CRCs were proximally located, in contrast to 30% of non-MSI cancers.
Older patients (≥65 years at diagnosis) frequently harbored BRAF (65%) or KRAS (56%)
mutations, although many lacked mutations in either gene (42%) (P = 0.0378 for either
mutation vs younger patients). Female patients had significantly more BRAF mutations
compared to males (BRAF mutant, 65%; KRAS mutant, 35%; wild type, 32%; P=0.0147 for
BRAF mutant vs. KRAS mutant, P=0.0033 for BRAF mutant vs. Wild type). BRAF and
KRAS mutant CRCs were significantly more common in the proximal colon, compared to Wild
type CRCs (BRAF mutant, 65%; KRAS mutant, 46%; wild type, 26%; P=0.0013 for BRAF
mutant vs. Wild type, P=0.0047 for KARS mutant vs. Wild type).
Importantly, BRAF mutations were detected at high frequencies in sporadic MSI tumors (67%),
were seldom present in non-MSI tumors (5%), and did not occur in Lynch syndrome patients
(0%). On the other hand, KRAS mutations were never present in sporadic MSI cancers (0%),
while 33% of Lynch syndrome and 35% of non-MSI CRC exhibited KRAS mutations.
Aberrant DNA hypermethylation is rare in normal colon, but is frequently observed in CRC
We investigated the methylation status at fourteen methylation-related loci using quantitative
COBRA in the total cohort of 487 colorectal tissues. We observed that 97% of CRCs (236/243),
46% of C-Ns (96/208) and 19% of N-Ns (7/36) showed evidence for methylation at ≥1 markers
(Figure 1A). Methylation levels in C-N and N-N tissues were quite low (<5% methylation) in
comparison to that observed in CRCs, suggesting the cancer-specificity of various methylation
markers (Figure 1B). Furthermore, the proportion of tissues with methylation at ≥2 loci was
significantly higher in CRCs (90%, 219/243) than in C-Ns (14%, 29/208) or N-Ns (3%, 1/36;
P<0.0001).
As shown in Table 3, the overall frequency of promoter hypermethylation at each gene/locus
was highly variable: SFRP2 (63%), RASSF2A (68%), MGMT (24%), Reprimo (24%),
3OST2 (82%), HPP1 (69%), APC (29%), hMLH1-5’ region (22%), hMLH1-3’ region (4%),
p16INK4a (17%), p14ARF (10%), MINT1 (12%), MINT2 (21%) and MINT31 (26%).
A distinct subset of markers is methylated in sporadic MSI versus Lynch syndrome CRCs
We correlated the methylation status at individual epigenetic markers in the MSI tumors (Table
3). When methylation features were compared between sporadic MSI and Lynch syndrome
tumors, as expected, sporadic MSI tumors were more frequently methylated at most of the
markers, the exceptions being: MINT31, SFRP2, and APC. Interestingly, aberrant methylation
at these three loci was more frequent in Lynch syndrome tumors. MINT31, which is one of the
canonical CIMP markers, was methylated at equal frequencies in Lynch syndrome CRCs
(62%) as in sporadic MSI (60%). Of potential importance for understanding the genesis of
tumors in Lynch syndrome, methylation at the APC promoter was more frequently observed
in Lynch syndrome CRCs (48%) in comparison to both sporadic MSI (27%) and non-MSI
(27%) tumors.
Hypermethylation frequency at individual markers is related to BRAF and KRAS mutational
status in CRC
We interrogated the relationship between methylation frequencies at each of the 14 epigenetic
markers and the presence or absence of BRAF/KRAS mutations in the total cohort of CRCs
(Table 3). We observed that the six classical CIMP-related markers (hMLH1-5’ region,
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hMLH1-3’ region, p16INK4a, MINT1, MINT2, and MINT31) along with Reprimo were
significantly more frequently methylated in BRAF mutant CRCs compared to the other
subgroups. However, we found that methylation frequencies at the other five markers
(SFRP2, RASSF2A, MGMT, 3OST2, and HPP1) were almost same or relatively higher in CRCs
harboring KRAS mutations. At the same time, APC methylation frequencies were comparable
in all three subsets (25% in BRAF mutants, 29% in KRAS mutants, and 29% in wild types).
Epigenetic alterations can be interpreted in the context of the mutational spectrum of the
KRAS-BRAF genes
We estimated the odds ratios (OR) for methylation at each marker among subgroups of CRCs
segregated by sporadic MSI/Lynch syndrome and BRAF/KRAS mutation status (Figure 2 and
Supplemental Table). When ORs were calculated for sporadic MSI vs Lynch syndrome CRCs,
we observed that methylation of all seven canonical CIMP markers, plus Reprimo, showed a
positive risk for methylation in sporadic MSI tumors (Figure 2A). Contrariwise, methylation
of MINT31 was significantly associated with Lynch syndrome cancers (OR, 5.74; 95%CI,
2.29–15.2). None of the other non-canonical epigenetic markers showed any risk associations
based upon MSI and/or Lynch syndrome status.
We then examined ORs for methylation at each marker among the subgroups of CRCs
categorized by BRAF/KRAS mutation status (Figure 2B). The ORs of the six canonical markers
(hMLH1-5’ region, hMLH1-3’ region, p16INK4a, MINT1, MINT2, and MINT31), together with
Reprimo were significantly higher in BRAF mutant CRCs, while five of the seven new markers
(SFRP2, RASSF2A, MGMT, 3OST2, and HPP1) showed significantly higher ORs in KRAS
mutant CRCs. Although the OR of p14ARF was the highest for BRAF mutant cancers, it was
not significantly different compared to other two subgroups. Similarly, the OR for APC
methylation was similar among various subsets (OR for BRAF mutant, 0.81; for KRAS mutant,
1.00; for wild type, 1.07). This analysis permitted us to categorize the epigenetic markers into
three distinct subsets: BRAF-related markers (hMLH1-5’ region, hMLH1-3’ region,
p16INK4a, MINT1, MINT2, MINT31, and Reprimo); KRAS-related markers (SFRP2,
RASSF2A, MGMT, 3OST2, and HPP1); and markers independent of the BRAF/KRAS
mutations (p14ARF and APC).
Aberrant DNA methylation is more frequent in Lynch syndrome CRCs than in non-MSI CRCs
Both Lynch syndrome CRCs and tumors with methylated hMLH1 promoters have the MSI
phenotype, but they arise through different pathways. To better understand the differences
between these types of CRCs, we determined the average numbers of methylated loci in each
subgroup of CRCs (Figure 3A and Table 4). When methylation data were utilized using all 14
epigenetic markers, the average number of methylated loci was highest in sporadic MSI CRCs
(8.4; 95%CI, 6.0–10.2), followed by Lynch syndrome CRCs (5.1; 95%CI, 4.1–6.2), and was
least in non-MSI CRCs (4.4; 95%CI, 4.1–4.8). Not surprisingly, when the data were analyzed
using only the canonical CIMP markers (hMLH1-5’ region, hMLH1-3’ region, p16INK4a,
p14ARF, MINT1, MINT2, and MINT31), the average number of methylated loci was
significantly higher in sporadic MSI CRCs (3.6; 95%CI, 2.3–4.9), compared to Lynch
syndrome (1.5; 95%CI, 1.0–2.0), or non-MSI subgroups (0.9; 95%CI, 0.7–1.0; P<0.0001).
However, interestingly, when the data were analyzed only using the seven additional
methylation markers, the differences in average number of methylated loci between Lynch
syndrome and non-MSI tumors became much smaller (sporadic MSI [4.8; 95%CI, 4.1–5.5],
Lynch syndrome [3.7; 95%CI, 3.0–4.4], non-MSI [3.6; 95%CI, 3.3–3.8]).
Furthermore, the average numbers of methylated loci were consistently higher for Lynch
syndrome CRCs compared with non-MSI CRCs (Table 4 and Figure 3A). More specifically,
Lynch syndrome CRCs showed significantly higher methylation when data were analyzed from
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seven CIMP canonical markers (1.5 versus 0.9; P=.0230). Although Lynch syndrome cancers
were more frequently methylated than non-MSI cancers, these data did not reach significance
when comparisons were drawn from 14 unselected epigenetic markers (5.1 versus 4.4;
P=0.2782), or the seven additional markers (3.7 versus 3.6; P=0.9977).
Comparable methylation frequencies occur in BRAF and KRAS mutant CRCs analyzed using
the additional epigenetic markers
We then determined whether the average numbers of methylated loci were influenced by the
presence of BRAF and KRAS mutations in CRC (Figure 3B and Table 4). When we used data
from all 14 markers, we observed that the average number of methylated loci was highest in
BRAF mutated tumors (8.0; 95%CI, 6. 5–9. 5), followed by KRAS mutants (5. 5; 95%CI, 5.0–
6.0) and the lowest in CRCs with wild-type BRAF and KRAS genes (3.9; 95%CI, 3.5–4.3;
P<0.0001). Similar findings were observed when data were analyzed from the seven canonical
CIMP markers alone (BRAF mutant [3.55; 95%CI, 2.7–4.4], KRAS mutant [1.2; 95%CI, 0.9–
1.5], wild type [0.7; 95%CI, 0.6–0. 9]; P<0.0001).
Interestingly, when the data were analyzed using the seven additional markers, the average
number of methylated loci in KRAS mutated cancers was no different than that in BRAF mutant
CRCs (BRAF mutant [4.4; 95%CI, 3.7–5.1], KRAS mutant [4.3; 95%CI, 4.0–4.6]; P=0.8610),
and average number of methylated loci in both of these subgroups was significantly higher
than in the tumors lacking mutations in both BRAF and KRAS [3.2; 95%CI, 2.9–3. 5];BRAF
vs Wild type, P<0.01; KRAS vs Wild type, P<0.0001).
Discussion
This study investigates the relationship between mutational activation in the RAS-RAF
signaling pathway and global hypermethylation using a panel of epigenetic markers in a cohort
of 487 colorectal tissues. More specifically, we asked whether CIMP in the colon is exclusively
correlated with BRAF mutations, or whether it may also associate with mutant KRAS, since
both genes are members of the same signaling pathway. Additionally, we asked whether CIMP
is primarily a disease of older individuals with sporadic MSI CRCs, or whether Lynch
syndrome CRCs may also have molecular features consistent with CIMP. We have provided
evidence that aberrant hypermethylation of various tumor suppressor genes and related loci
not only associate with mutant BRAF, but also with mutant KRAS, and that activation of the
KRAS-BRAF pathway induces aberrant promoter methylation in multiple genes. Additionally,
we found that Lynch syndrome CRCs have frequent methylation, challenging the supposition
that CIMP is exclusively a molecular characteristic of sporadic CRCs.
Although the CIMP concept was first proposed in CRC almost a decade ago 2, only recently
has evidence supported its existence in a specific subset of sporadic CRCs 3,4,8,9. In spite of
this, the molecular basis of CIMP remains unclear and is a matter of active investigation.
Currently, CIMP CRCs are characterized using a panel of markers that were selected, in part,
through their association with the V600E BRAF mutation 11–13. Although the canonical
CIMP-related markers are highly specific, this panel may not be completely adequate, as there
is no consensus on the frequency of CIMP in CRC 8,9. Part of the problem may be attributed
to differences in methodologies for measuring methylation in each laboratory, but central to
this issue is a lack of consensus criteria and definitions for CIMP in CRC 8,9,14,15. Moreover,
some studies have reported data in which a subset of CRCs have intermediate levels of aberrant
DNA methylation defined as CIMP-low, as they failed to meet the more restrictive criteria for
CIMP 14,32–35. This has led others to challenge the methylator phenotype as a discrete
“pathway” in colorectal carcinogenesis.
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Herein, we present data that clearly suggest that CIMP-associated aberrant methylation
observed in CRCs may not be limited to those with V600E BRAF mutations. Rather, CIMP
determination appears to be dependent upon the choice of methylation markers. When data are
analyzed using canonical CIMP-related markers, one can identify a distinct cluster of CRCs
that are strongly associated with mutant BRAF 14,33. However, this tight clustering of CRC
disappears when additional epigenetic markers are analyzed. We demonstrate that when data
are evaluated from canonical markers, BRAF mutant CRCs have the highest average number
of methylated loci. However, when additional methylation markers are analyzed, both BRAF
and KRAS mutated cancers show similar degrees of methylation, and methylation levels in
these two subgroups are significantly higher than in CRCs that are wild-type for these genes.
In comparison to the classical CIMP markers that strongly associate with mutant BRAF, data
analysis with non-canonical methylation markers in our study resulted in loss of the typical
bimodal distribution observed for CIMP-positive and negative tumors. However, these data
are biologically relevant since a significant amount of aberrant methylation was associated
with mutant KRAS. Additionally, when data were analyzed from only non-CIMP markers,
KRAS mutated and wild type CRCs were statistically distinguishable from each other (Table
4). Similar suggestions have been made in previous studies 11,36. It is difficult to directly
compare our panel of non-canonical CIMP markers with the markers interrogated in the
previous studies 11,36. A common feature among these studies is the suggestion that a
significant amount of methylation positively associates with mutant KRAS in the colon. Since
KRAS and BRAF belong to the same growth signaling pathway, these data argue that activating
mutations in either of these genes may have equivalent effects in mediating aberrant DNA
methylation. This brings the RAS/RAF story full circle, as it was initially found that KRAS
mutations were responsible for upregulating DNA methylation and a methylator phenotype in
vitro 20. In support of this, a recent study has clearly shown that Ras-mediated epigenetic
silencing occurs through a specific, but complex pathway, involving components that are
essential for maintaining a fully transformed phenotype in a fibroblast cell line 37.
It has been proposed that CIMP CRCs that harbor BRAF mutations and demonstrate MSI may
originate through a unique pathway that includes the progression of sessile serrated polyps to
MSI CRCs 38. It has been suggested that V600E BRAF mutations are present in sessile serrated
polyps and serrated aberrant crypt foci (ACF), whereas, KRAS mutations are more highly
associated with non-serrated polyps and ACFs 32,39. Interestingly, 90% of ACF with BRAF
mutations were found to be MSS 39. Approximately 70% of sporadic MSI-H CRCs exhibit
BRAF mutations and a majority of sporadic MSI-H CRCs are caused by extensive
hypermethylation of the hMLH1 gene 17,32. Our data and that from others suggest that aberrant
DNA methylation may be induced by upregulation of the RAS-RAF pathway 37, and that
genetic alteration in BRAF or KRAS might be an earlier event that precedes aberrant DNA
methylation.
In this study we noticed a positive association of RASSF2A methylation with mutant KRAS,
which contradicts an earlier report 23. However, the study by Hesson and colleagues 23
involved a small subset of tissues (8 adenomas, and 33 carcinomas). A subsequent study
analyzed a cohort of 140 CRCs, and reported that 67% of CRCs with RASSF2 methylation
displayed BRAF or KRAS mutations (P=0.0009), and showed that inactivation of RASSF2
enhanced KRAS-induced oncogenic transformation 25. Our present data are in agreement with
this recent study, and we feel confident that our data are reliable, and that RASSF2A
methylation positively associates with mutant KRAS in the colon.
CIMP predominantly occurs in older individuals with sporadic MSI CRCs, but it has not been
rigorously investigated in Lynch syndrome 32,40. In this study, we observed that sporadic MSI
CRCs had the highest degree of aberrant methylation regardless of the epigenetic markers
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analyzed 32. However, unexpectedly, we observed that Lynch syndrome patients, who were
much younger, had higher degree of methylation than that of non-MSI CRCs, particularly when
data were analyzed from seven canonical CIMP markers (P=0.023). It is possible that the higher
degree of methylation observed in Lynch syndrome may be due, in part, to methylation events
associated with the frequent KRAS mutations.
In the past decade, the efforts of several labs have been focused upon the molecular mechanisms
of aberrant DNA methylation, but our current understanding into these processes is limited.
Although this study does not provide a conclusive explanation for the specific processes that
control DNA methylation, but our data provide indirect evidence that highlight the importance
of KRAS-associated methylation events. We also found that aberrant DNA methylation is a
much more common event in Lynch syndrome patients than was previously presumed. We
speculate that genetic alterations in the BRAF and KRAS oncogenes is an early event in the
evolution of a methylator phenotype, and that regulation of aberrant DNA methylation may be
located downstream in the RAS-RAF signaling pathway. Finally, considering the paucity of
information on the causes of CIMP, in the future studies it may be prudent to interpret aberrant
DNA methylation in the context of mutations in both BRAF and KRAS genes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Frequent hypermethylation at multiple loci in CRCs
A) Distribution of all colorectal tissue specimens based upon the number of methylated
promoter loci. CRC denotes colorectal cancer; C-N denotes corresponding normal colonic
epithelium; N-N denotes normal colonic epithelium without neoplasia at colonoscopy.
B) The figure illustrates COBRA data for seven canonical CIMP-related markers (hMLH1-5’
region, hMLH1-3’ region, p16INK4a, p14ARF, MINT1, MINT2 and MINT31) and the seven
new markers (SFRP2, RASSF2A, MGMT, Reprimo, 3OST2, HPP1 and APC) in CRCs (T),
corresponding normal colonic epithelium (N) and normal colonic epithelium without neoplasia
on colonoscopy (NN). Mc indicates SssI methylase-treated control human genomic DNA. PCR
conditions of p16, MINT1, MINT2, and MINT31 were described previously by Rashid et al.,
35; and for that of p14 by Shen et al.,15
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Figure 2. The odds ratio (OR) for methylation at each epigenetic marker in subgroups of CRCs
categorized by MSI status (sporadic or Lynch syndrome) (panel A), or BRAF/KRAS mutational
status (panel B)
A) The upper, middle, and bottom panels illustrate the ORs for sporadic MSI tumors (MSI),
Lynch syndrome CRCs, and non-MSI CRCs, respectively.
B) The upper, middle, and bottom panels illustrate the ORs for BRAF mutant CRCs (BRAF),
KRAS mutant CRCs (KRAS), and wild type (both wild type) CRCs, respectively.
The vertical bars depict the 95% CIs for this ratio. An odds ratio (OR) >1.0 for a given marker
is represented by a white square and suggests a positive association with that subgroup (>1.0),
while an OR <1.0 represents a negative risk and is shown as black squares. An OR for an
epigenetic marker that does not show any positive or negative associations is shown in gray.
All odds ratios are presented in a log scale.
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Figure 3. Average numbers of methylated loci in various subgroups of CRCs categorized by MSI
status (panel A) or BRAF/KRAS mutation status (panel B)
The average number of methylated loci in each subset was calculated by all fourteen markers
(all Loci), seven canonical CIMP markers (CIMP-related) or the seven additional markers
(additional markers). In the box-plot diagrams, the horizontal line within each box represents
the median; the limits of each box are the inter-quartile ranges, the whiskers are the maximum
and minimum values, and the blue cross within each box depicts the mean value. The numbers
above each box denotes the mean number of methylated loci. The P values above the square
panels were based on Kruskal-Wallis one way analysis of variance on ranks, and represents
the statistical differences in average methylation among all three subsets (sporadic MSI, Lynch
syndrome and non-MSI) of CRCs. Statistical differences among any two individual groups are
shown as pair-wise comparisons in Table 4.
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Table 1
Primer sequences, Restriction endonuclease and PCR conditions for COBRA
Locus Primer Sequence Product Size
(Restriction Enzyme)
Temperature
(Degrees in Celsius)
hMLH1-5 F; 5′YGGGTAAGTYGTTTTGAYGTAGA3′ 148 (HhaI) 59 (5), 57 (10), 55 (30)
R; 5′ATACCTAATCTATCRCCRCCTCATC3′
hMLH1-3 F; 5′GGGAGGGAYGAAGAGATTTAGT3′ 160 (RsaI) 59 (5), 57 (10), 55 (30)
R; 5′ACCTTCAACCAATCACCTCAAT3′
p16INK4a F; 5′GGTTTTGGYGAGGGTTGTTT3′ 181 (TaqI) 58 (3), 56 (7), 54 (15), 52 (20)#
R; 5′ACCCTATCCCTCAAATCCTCTAAAA3′
p14ARF F; 5′TTTYGGGGYGGAGATGGGT3′ 160 (TaqI) 60 (45)##
R; 5′ATCACCAAAAACCTACRCACCATATTC3′
MINT1 F; 5′GGGTTGGAGAGTAGGGGAGTT3′ 199 (TaqI) 55 (45)#
R; 5′CCATCTAAAATTACCTCRATAACTTA3′
MINT2 F; 5′YGTTATGATTTTTTTGTTTAGTTAAT3′ 203 (TaqI) 60 (3), 58 (7), 56 (15), 54 (20)#
R; 5′TACACCAACTACCCAACTACCTC3′
MINT31 F; 5′GAYGGYGTAGTAGTTATTTTGTT3′ 185 (HpyCH4IV) 58 (3), 56 (7), 54 (15), 52 (20)#
R; 5′CATCACCACCCCTCACTTTAC3′
SFRP2 F; 5′GGTTGTTAGTTTTTYGGGGTTT3′ 148 (HhaI) 59 (5), 57 (10), 55 (30)
R; 5′AACCAAAACCCTACAACATCRT3′
RASSF2A F; 5′TTGGGGAGGGTTTGATAGTTT3′ 131 (TaqI) 62 (5), 60 (10), 58 (30)
R; 5′CRCACCCTACRCCCCTCTAAAA3′
MGMT F; 5′GTTTTTAGAAYGTTTTGYGTTT3′ 145 (BstUI) 53 (10), 50 (35)
R; 5′CCTACAAAACCACTCRAAACTA3′
Reprimo F; 5′GGGTTGGTTTAGTTTYGTTAAGTTT3′ 138 (TaqI) 60 (15), 58 (30)
R; 5′TAAAAATTTCCCAAAAACCTCTCC3′
3OST2 F; 5′TTTGGTTAGTAGTTTTIGGAGAAGA3′ 171 (TaqI) 60 (5), 58 (10), 56 (30)
R; 5′CCCTATAAACCATAACTCCATAAACC3′
HPP1 F; 5′TGTTTAGTAGTTYGTTGTTYGGTTT3′ 137 (NruI) 58 (5), 56 (10), 54 (30)
R; 5′AACCCTCGCAAAATATCCAAC3′
APC F; 5′GGTTTTGTGTTTTATTGYGGAGTG3′ 156 (TaqI) 60 (45)
R; 5′CACCAATACAACCACATATCIATCAC3′
#
PCR conditions described previously by Rashid et al., 35
##
Shen et al., 15
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Table 4
Pair-wise comparisons of methylation levels for various epigenetic markers with different subgroups of CRCs
segregated based upon their MSI status and BRAF/KRAS mutation status
Subset of Markers MSI status P value BRAF/KRAS mutation status P value
Pairwise Comparison Pairwise Comparison
All Markers Sporadic MSI vs. Lynch
Syndrome
0.0101 BRAF vs. KRAS 0.0042
Sporadic MSI vs. Non-MSI 4.22e-05 BRAF vs. Wild type 2.56e-06
Lynch syndrome vs. Non-MSI 0.2782 KRAS vs. Wild type 1.40e-05
CIMP Markers Sporadic MSI vs. Lynch
Syndrome
1.23e-02 BRAF vs. KRAS 3.44e-06
Sporadic MSI vs. Non-MSI 1.46e-05 BRAF vs. Wild type 1.05e-06
Lynch syndrome vs. Non-MSI 0.0230 KRAS vs. Wild type 0.0353
Additional Markers Sporadic MSI vs. Lynch
Syndrome
0.0509 BRAF vs. KRAS 0.8610
Sporadic MSI vs. Non-MSI 0.0124 BRAF vs. Wild type 0.00883
Lynch syndrome vs. Non-MSI 0.9977 KRAS vs. Wild type 1.95e-05
P values were based on Steel-Dwass test.
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